The product, known as HP802-247, was viewed by some analysts as a key pipeline asset in the company's advanced wound management division and the Phase III failure is a setback for the healthcare group, which is a regular subject of takeover talk.
The unsuccessful North American trial, announced on Monday, is also something of a surprise, given the promise of earlier studies.
http://in.reuters.com/article/2014/10/13/us-smith-nephew-skin-idINKCN0I20EN20141013?feedType=RSS&feedName=health&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%253A+reuters%252FINhealth+%2528News+%252F+IN+%252F+Health%2529
No comments:
Post a Comment